101 related articles for article (PubMed ID: 7853190)
1. Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
Hilditch A; Hunt AA; Travers A; Polley J; Drew GM; Middlemiss D; Judd DB; Ross BC; Robertson MJ
J Pharmacol Exp Ther; 1995 Feb; 272(2):750-7. PubMed ID: 7853190
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the inhibitory effect of N(G)-nitro-L-arginine methyl ester on the antihypertensive effect of the angiotensin AT1 receptor antagonist, GR138950.
Anderson IK; Drew GM
Br J Pharmacol; 1997 Dec; 122(7):1385-94. PubMed ID: 9421286
[TBL] [Abstract][Full Text] [Related]
3. The antihypertensive profile of the angiotensin AT1 receptor antagonist, GR138950, and the influence of potential homeostatic compensatory mechanisms in renal hypertensive rats.
Anderson IK; Drew GM
Br J Pharmacol; 1998 Nov; 125(6):1236-46. PubMed ID: 9863652
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of DuP 532, a selective and noncompetitive AT1 receptor antagonist.
Wong PC; Hart SD; Chiu AT; Herblin WF; Carini DJ; Smith RD; Wexler RR; Timmermans PB
J Pharmacol Exp Ther; 1991 Nov; 259(2):861-70. PubMed ID: 1941632
[TBL] [Abstract][Full Text] [Related]
5. Further investigations into the mechanism of the antihypertensive activity of the angiotensin AT1 receptor antagonist, GR138950.
Hilditch A; Prior HM; Drew GM
Br J Pharmacol; 1996 Jun; 118(3):711-9. PubMed ID: 8762098
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, U-97018.
Kushida H; Nomura S; Morita O; Harasawa Y; Suzuki M; Nakano M; Ozawa K; Kunihara M
J Pharmacol Exp Ther; 1995 Sep; 274(3):1042-53. PubMed ID: 7562467
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566.
Edwards RM; Aiyar N; Ohlstein EH; Weidley EF; Griffin E; Ezekiel M; Keenan RM; Ruffolo RR; Weinstock J
J Pharmacol Exp Ther; 1992 Jan; 260(1):175-81. PubMed ID: 1309870
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of SC-52458, an orally active, nonpeptide angiotensin AT1 receptor antagonist.
Olins GM; Corpus VM; Chen ST; McMahon EG; Palomo MA; McGraw DE; Smits GJ; Null CL; Brown MA; Bittner SE
J Cardiovasc Pharmacol; 1993 Oct; 22(4):617-25. PubMed ID: 7505365
[TBL] [Abstract][Full Text] [Related]
9. Effects of the angiotensin AT1 receptor antagonist GRI38950 on haemodynamic function in dogs.
Hunt AA; Hilditch A; Drew GM
J Auton Pharmacol; 1997 Feb; 17(1):1-11. PubMed ID: 9201554
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist.
Hilditch A; Hunt AA; Gardner CJ; Twissell DJ; Polley J; Travers A; Drew GM; Middlemiss D; Ross BC; Robertson MJ
Br J Pharmacol; 1994 Jan; 111(1):137-44. PubMed ID: 8012689
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonist.
Cirillo R; Renzetti AR; Cucchi P; Guelfi M; Salimbeni A; Caliari S; Castellucci A; Evangelista S; Subissi A; Giachetti A
Br J Pharmacol; 1995 Mar; 114(6):1117-24. PubMed ID: 7620700
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
Criscione L; de Gasparo M; Bühlmayer P; Whitebread S; Ramjoué HP; Wood J
Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
[TBL] [Abstract][Full Text] [Related]
13. Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent.
Wong PC; Price WA; Chiu AT; Duncia JV; Carini DJ; Wexler RR; Johnson AL; Timmermans PB
J Pharmacol Exp Ther; 1990 Feb; 252(2):726-32. PubMed ID: 2179532
[TBL] [Abstract][Full Text] [Related]
14. Sympatho-inhibitory properties of various AT1 receptor antagonists.
Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
J Hypertens Suppl; 2002 Jun; 20(5):S3-11. PubMed ID: 12184061
[TBL] [Abstract][Full Text] [Related]
15. Characterization of angiotensin II antagonism displayed by Ib, a novel nonpeptide angiotensin AT(1) receptor antagonist.
Wu J; Wang Q; Guo J; Hu Z; Yin Z; Xu J; Wu X
Eur J Pharmacol; 2008 Jul; 589(1-3):220-4. PubMed ID: 18571160
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist.
Robertson MJ; Barnes JC; Drew GM; Clark KL; Marshall FH; Michel A; Middlemiss D; Ross BC; Scopes D; Dowle MD
Br J Pharmacol; 1992 Dec; 107(4):1173-80. PubMed ID: 1467838
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic characterization of CI-996, a new angiotensin receptor antagonist.
Keiser JA; Ryan MJ; Panek RL; Hodges JC; Sircar I
J Pharmacol Exp Ther; 1995 Mar; 272(3):963-9. PubMed ID: 7891350
[TBL] [Abstract][Full Text] [Related]
18. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.
Wong PC; Price WA; Chiu AT; Duncia JV; Carini DJ; Wexler RR; Johnson AL; Timmermans PB
J Pharmacol Exp Ther; 1990 Oct; 255(1):211-7. PubMed ID: 2213556
[TBL] [Abstract][Full Text] [Related]
19. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent.
Wong PC; Price WA; Chiu AT; Duncia JV; Carini DJ; Wexler RR; Johnson AL; Timmermans PB
J Pharmacol Exp Ther; 1990 Feb; 252(2):719-25. PubMed ID: 2179531
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist.
Mochizuki S; Sato T; Furuta K; Hase K; Ohkura Y; Fukai C; Kosakai K; Wakabayashi S; Tomiyama A
J Cardiovasc Pharmacol; 1995 Jan; 25(1):22-9. PubMed ID: 7723348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
